Acceptability, safety and premenstrual symptomatology in women using an
oral contraceptive containing gestodene 60mcg/ethinylestradiol 15mcg
I.C. Barbosa (1), D. Faggion Jr. (2), C. Isaia Filho (3), E.C. Baracat
(4), R. Acquaroli (5)
Department of Obstetrics, Gynecology and Human Reproduction, Federal
University of Bahia, Salvador, Bahia, Brazil (1); DFJ Clinica Médica, Säo
Paulo, Brazil (2); Centro de Medicina Reprodutiva Dr. Carlos Isaia Filho, Porto
Alegre, Brazil (3); Säo Paulo Hospital, Federal University of Säo Paulo,
Brazil (4); Wyeth Pharmaceutical, Säo Paulo, Brazil (5)
This presentation will focus on previously unpublised data on the
acceptability, safety and efficacy in a group of healthy women using an
ultra-low dose oral contraceptive containing gestodene 60mcg/ethinylestradiol
15mcg (Minesse®). The data will give an overview of an open, non-comparative,
multicenter study carried out in Brazil, involving 163 women aged 18–39 years
(mean 25+5 years) treated with an oral regimen of gestodene 60mcg/ethinylestradiol
15mcg daily from day 1–24 of the menstrual cycle, followed by a 4-day
pill-free interval from day 25–28 of the cycle.
